Molecular basis of agonism and antagonism in the oestrogen receptor
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Oestrogens are involved in the growth, development and homeostasis of a number of tissues. The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER). Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of molecular events culminating in the activation or repression of target genes. Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery. Here we report the crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17beta-oestradiol, and the selective antagonist raloxifene, at resolutions of 3.1 and 2.6 A, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties. Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes. In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We previously found that the full-length ERα dimer forms a symmetric tail-to-tail dimer in the ERα/SRC-3/p300 complex (Yi et al., 2015), consistent with the nature of palindromic DNA binding sequence, symmetric X-ray crystal structures of the ERα LBD (Brzozowski et al., 1997) and DBD dimers (Schwabe et al., 1993).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
In the citing paper
“the AR LBD interacts weakly with LXXLL motif-containing coactivators, such as SRCs, (Brzozowski et al., 1997; Dubbink et al., 2006; He et al., 2004; He et al., 1999; Matias et al., 2000; Nadal et al., 2017).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · cited 1×
“Data were integrated and reduced using the programs DENZO and SCALEPAC”
MethodPROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.2.127 · Cited by 5,690
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932 · cited 1×
“The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER”
BackgroundThe estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220 · cited 1×
“The ER LBDs are arranged as non-crystallographic dimers within both the E 2 and RAL complex crystals in a manner consistent with both the oligomeric state of liganded ER in solutio”
BackgroundCrystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/375377a0 · Cited by 1,177 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundCrystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid
Renaud, J.-P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/378681a0 · Cited by 1,097 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundA canonical structure for the ligand-binding domain of nuclear receptors
Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D., & Gronemeyer, H. (1996) · Nature Structural Biology · doi:10.1038/nsb0196-87 · Cited by 985 · cited 1×
“, and emphasizes the universal nature of this fold within this receptor superfamil”
Background
Cited by
Items 101–200 of 1,012
Sack, J. S., Kish, K. F., Wang, C., Attar, R. M., Kiefer, S. E., An, Y., Wu, G. Y., Scheffler, J. E., Salvati, M. E., Krystek, S. R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081565498 · Cited by 491
Estrogen receptor interaction with co-activators and co-repressors☆
Klinge, C. M. (2000) · Steroids · doi:10.1016/s0039-128x(99)00107-5 · Cited by 491
Role of Estrogen Receptor Beta in Estrogen Action
Pettersson, K., & Gustafsson, J.-Å. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.165 · Cited by 491
Self-citationNormal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family
Xu, J., Wu, R.-C., & O'Malley, B. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2695 · Cited by 488
“Protein expression IHC High in 19% of tumours (150) ERβ and ERBB2 Recurrence and poor DFS 85”
BackgroundBreast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
“This binding changes the conformation of the ER ligand-binding domain, and once ER is translocated to the nucleus, it blocks co-factor recruitment and subsequent genes transcription involved in cell cycle progression (cyclin D1), cell proliferation (like IGF-1), or cell migration (collagenase) [69,70].”
BackgroundMolecular mechanism of estrogen–estrogen receptor signaling
Yaşar, P., Ayaz, G., User, S. D., Güpür, G., & Muyan, M. (2017) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12006 · Cited by 482
Bourguet, W., Germain, P., & Gronemeyer, H. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01548-0 · Cited by 482
Estrogen receptor phosphorylation
Lannigan, D. A. (2003) · Steroids · doi:10.1016/s0039-128x(02)00110-1 · Cited by 480
“The position of helix 12, relative to the body of the LBD, determines whether or not a ligand behaves as an agonist or an antagonist [38,40,41] .”
BackgroundPhytoestrogens: a review of the present state of research
Ososki, A. L., & Kennelly, E. J. (2003) · Phytotherapy Research · doi:10.1002/ptr.1364 · Cited by 479
“Two ring structures separated with two carbon atoms as well as spacing between hydrophobic and hydrogen bond interactions are also important in binding affinity to ERs (Brzozowski et al., 1997).”
BackgroundAntiestrogen resistance in breast cancer and the role of estrogen receptor signaling
Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O'Brien, K., Wang, Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206937 · Cited by 478
“Perhaps the most important information has come from crystallographic studies of the ER binding domain complexed with different ligands (Brzozowski et al., 1997; Pike et al., 1999; Shiau et al., 2002).”
BackgroundMatthews, J. B., Twomey, K., & Zacharewski, T. R. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0001833 · Cited by 465
Combinatorial roles of nuclear receptors in inflammation and immunity
Glass, C. K., & Ogawa, S. (2006) · Nature Reviews Immunology · doi:10.1038/nri1748 · Cited by 464
“For example, the selective oestrogen-receptor modulators tamoxifen and raloxifene distort AF2 so that it cannot bind LXXLL-motif-containing co-activator”
BackgroundTop, S., Vessières, A., Leclercq, G., Quivy, J. I., Tang, J., Vaissermann, J., Huché, M., & Jaouen, G. (2003) · Chemistry - A European Journal · doi:10.1002/chem.200305024 · Cited by 455
Hawkins, M. B., Thornton, J. W., Crews, D., Skipper, J. K., Dotte, A., & Thomas, P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.20.10751 · Cited by 449
Fang, H., Tong, W., Shi, L. M., Blair, R., Perkins, R., Branham, W., Hass, B. S., Xie, Q., Dial, S. L., Moland, C. L., et al. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000208y · Cited by 449
“The recently reported crystal structure of the ER-E2 complex reveals that the 3- and 17‚-OH groups primarily serve as H-bond donors and acceptors in interacting with the receptor binding site ( 20 ).”
BackgroundInfluentialDeep Docking: A Deep Learning Platform for Augmentation of Structure Based Drug Discovery
Gentile, F., Agrawal, V., Hsing, M., Ton, A.-T., Ban, F., Norinder, U., Gleave, M. E., & Cherkasov, A. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00229 · Cited by 447
He, B., Kemppainen, J. A., & Wilson, E. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002807200 · Cited by 442
The Estrogen Receptor β Subtype: A Novel Mediator of Estrogen Action in Neuroendocrine Systems
Kuiper, G. G. J. M., Shughrue, P. J., Merchenthaler, I., & Gustafsson, J.-Å. (1998) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1998.0170 · Cited by 439
Self-citationPalmitoylation-dependent Estrogen Receptor α Membrane Localization: Regulation by 17β-Estradiol
Acconcia, F., Ascenzi, P., Bocedi, A., Spisni, E., Tomasi, V., Trentalance, A., Visca, P., & Marino, M. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0547 · Cited by 438
“Moreover, the E2 binding to the soluble, cytosolic, receptor, enacting ER structural modifications ( Brzozowski et al., 1997 ), could impair the PAT action (i.e., PAT:ER recognition).”
BackgroundThe structure of the nuclear hormone receptors
Kumar, R., & Thompson, E. B. (1999) · Steroids · doi:10.1016/s0039-128x(99)00014-8 · Cited by 435
“[60] Brzozowski AM, Piki ACW, Dauter Z, Hubbard RE, Bonn T, Eng-”
BackgroundInfluentialThe potential for estradiol and ethinylestradiol degradation in english rivers
Jürgens, M. D., Holthaus, K. I. E., Johnson, A. C., Smith, J. J. L., Hetheridge, M., & Williams, R. J. (2002) · Environmental Toxicology and Chemistry · doi:10.1002/etc.5620210302 · Cited by 435
Increasing the Complexity of Coactivation in Nuclear Receptor Signaling
Freedman, L. P. (1999) · Cell · doi:10.1016/s0092-8674(00)80708-4 · Cited by 434
Wijayaratne, A. L., & McDonnell, D. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101097200 · Cited by 427
Peroxisome Proliferator-Activated Receptors: From Genes to Physiology
Kliewer, S. A. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.239 · Cited by 425
Activation of Estrogen Receptor-α by the Heavy Metal Cadmium
Stoica, A., Katzenellenbogen, B. S., & Martin, M. B. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.4.0441 · Cited by 424
CAR and PXR: The xenobiotic-sensing receptors☆
Timsit, Y. E., & Negishi, M. (2007) · Steroids · doi:10.1016/j.steroids.2006.12.006 · Cited by 423
Arnal, J.-F., Lenfant, F., Metivier, R., Flouriot, G., Henrion, D., Adlanmerini, M., Fontaine, C., Gourdy, P., Chambon, P., Katzenellenbogen, B., et al. (2017) · Physiological Reviews · doi:10.1152/physrev.00024.2016 · Cited by 418
“C. Roles of ER AF-2 and of DNA Recognition by ER To assess the role of ER AF-2, a targeted deletion of 7 amino acids (543–549) (ER AF-2° mice) (28) (FIGURE 1E), or two point mutations L543A and L544A (ER AF-2-KI mice) (13), have been introduced in the H12 using knock-in strategies in mice.”
BackgroundInfluentialJordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020449y · Cited by 414
Menuet, A., Pellegrini, E., Anglade, I., Blaise, O., Laudet, V., Kah, O., & Pakdel, F. (2002) · Biology of Reproduction · doi:10.1095/biolreprod66.6.1881 · Cited by 413
“Five conserved motifs involved in E2 binding [33, 34] were found in each zfER (Fig.”
BackgroundEstrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β
Paige, L. A., Christensen, D. J., Grøn, H., Norris, J. D., Gottlin, E. B., Padilla, K. M., Chang, C.-Y., Ballas, L. M., Hamilton, P. T., McDonnell, D. P., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3999 · Cited by 412
Roy, A. K., Lavrovsky, Y., Song, C. S., Chen, S., Jung, M. H., Velu, N. K., Bi, B. Y., & Chatterjee, B. (1998) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)60938-3 · Cited by 411
Mechanism of the nuclear receptor molecular switch
NAGY, L. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.04.006 · Cited by 410
Estrogen-Like Activity of Metals in Mcf-7 Breast Cancer Cells
Martin, M. B., Reiter, R., Pham, T., Avellanet, Y. R., Camara, J., Lahm, M., Pentecost, E., Pratap, K., Gilmore, B. A., Divekar, S., et al. (2003) · Endocrinology · doi:10.1210/en.2002-221054 · Cited by 409
ICI 182,780 (Faslodex?): Development of a novel, ?pure? antiestrogen
Howell, A., Osborne, C. K., Morris, C., & Wakeling, A. E. (2000) · Cancer · doi:10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6 · Cited by 408
Tzameli, I., Pissios, P., Schuetz, E. G., & Moore, D. D. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.2951-2958.2000 · Cited by 408
“7A), and other receptors (4, 21, 26, 33, 36), these residues are known to make specific contacts with ligands.”
BackgroundCrystal Structure of a Heterodimeric Complex of RAR and RXR Ligand-Binding Domains
Bourguet, W., Vivat, V., Wurtz, J.-M., Chambon, P., Gronemeyer, H., & Moras, D. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80424-4 · Cited by 403
To ERR in the estrogen pathway
Giguére, V. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(02)00592-1 · Cited by 401
Estrogen Receptor Mutations in Human Disease
Herynk, M. H., & Fuqua, S. A. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0010 · Cited by 400
“ERs in human disease (59 – 61), ER structure and function (62), ER interaction with other cellular signaling molecules (63, 64), ER coregulators (62, 65, 66), and the pharmacology of selective estrogen receptor modulators (SERMs) (67, 68), are also extensively reviewed elsewhere, and hence will only be modestly review…”
BackgroundResultInfluentialCellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Clarke, R., Leonessa, F., Welch, J. N., & Skaar, T. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01479-0 · Cited by 397
Webb, P. M., Nguyen, P. T., Valentine, C. D., Lopez, G. N., Kwok, G. R., McInerney, E. M., Katzenellenbogen, B. S., Enmark, E., Gustafsson, J.-Α., Nilsson, S. V., et al. (1999) · Molecular Endocrinology · doi:10.1210/me.13.10.1672 · Cited by 396
“Antiestrogens, including tamoxifen, raloxifene, and ICI 182,780 (ICI), block formation of AF-2, thereby reducing coactivator complex recruitment (31, 32, 39), and restrict ERa AF-1 activity by promoting association with corepressors (40–45).”
BackgroundSelf-citationJordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020450x · Cited by 396
27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen
Umetani, M., Domoto, H., Gormley, A. K., Yuhanna, I. S., Cummins, C. L., Javitt, N. B., Korach, K. S., Shaul, P. W., & Mangelsdorf, D. J. (2007) · Nature Medicine · doi:10.1038/nm1641 · Cited by 396
“ERs have relatively large ligand binding pockets, permitting several pharmacophores, including SERMs, to bind and modulate their functio”
BackgroundSelective Estrogen Receptor Modulators
Frasor, J., Stossi, F., Danes, J. M., Komm, B., Lyttle, C. R., & Katzenellenbogen, B. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3326 · Cited by 395
FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent
Stenoien, D. L., Patel, K., Mancini, M. G., Dutertre, M., Smith, C. L., O'Malley, B. W., & Mancini, M. A. (2001) · Nature Cell Biology · doi:10.1038/35050515 · Cited by 393
“; these are revealed when agonist binding causes a conformational change that involves repositioning of the conserved helix 12 (ref”
BackgroundTranscriptional cross-talk, the second mode of steroid hormone receptor action
Göttlicher, M., Heck, S., & Herrlich, P. (1998) · Journal of Molecular Medicine · doi:10.1007/s001090050242 · Cited by 388
Oestrogen receptors – an overview
Enmark, E., & Gustafsson, J. ‐. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00545.x · Cited by 380
Self-citationY. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Peptide Antagonists of the Human Estrogen Receptor
Norris, J. D., Paige, L. A., Christensen, D. J., Chang, C.-Y., Huacani, M. R., Fan, D., Hamilton, P. T., Fowlkes, D. M., & McDonnell, D. P. (1999) · Science · doi:10.1126/science.285.5428.744 · Cited by 373
Filardo, E. J. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00190-x · Cited by 373
He, B., Kemppainen, J. A., Voegel, J. J., Gronemeyer, H., & Wilson, E. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37219 · Cited by 372
Targeted photodynamic therapy via receptor mediated delivery systems
Sharman, W. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.08.015 · Cited by 372
Estrogen: Consequences and Implications of Human Mutations in Synthesis and Action1
Grumbach, M. M., & Auchus, R. J. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.12.6290 · Cited by 368
Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use
Osborne, C. K., Zhao, H. (., & Fuqua, S. A. W. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3172 · Cited by 367
Platet, N., Cathiard, A. M., Gleizes, M., & Garcia, M. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.02.001 · Cited by 367
“On a molecular basis, they trigger inactive conformation of the ER , which is then unable to activate transcription via activating function AF2 [9-11 , 15-17 These initial data obtained in cell lines or animal tissues were largely confirmed by clinical studies developed with this compound in the last decades.”
BackgroundInfluentialNuclear Receptor Structure: Implications for Function
Bain, D. L., Heneghan, A. F., Connaghan-Jones, K. D., & Miura, M. T. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.031905.160308 · Cited by 366
Chang, C.-Y., Norris, J. D., Grøn, H., Paige, L. A., Hamilton, P. T., Kenan, D. J., Fowlkes, D., & McDonnell, D. P. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.12.8226 · Cited by 364
“The crystal structures of raloxifene-, tamoxifen-, and estradiol-activated ERa HBD have recently been solved and indicate that the coactivator binding groove within the receptor is occupied by a mispositioned helix 12 upon antagonist binding (4, 41).”
BackgroundQSAR Models Using a Large Diverse Set of Estrogens
Shi, L. M., Fang, H., Tong, W., Wu, J., Perkins, R., Blair, R. M., Branham, W. S., Dial, S. L., Moland, C. L., & Sheehan, D. M. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000066d · Cited by 363
Differential Effects of Xenoestrogens on Coactivator Recruitment by Estrogen Receptor (ER) α and ERβ
Routledge, E. J., White, R., Parker, M. G., & Sumpter, J. P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006777200 · Cited by 362
Oestrogenic activity of parabens in MCF7 human breast cancer cells
Byford, J. R., Shaw, L. E., Drew, M. G. B., Pope, G. S., Sauer, M. J., & Darbre, P. D. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00174-1 · Cited by 361
Reflections on the Discovery and Significance of Estrogen Receptor β
Koehler, K. F., Helguero, L. A., Haldosén, L.-A., Warner, M., & Gustafsson, J.-A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0027 · Cited by 360
“ICI182,780 is a derivative of E2 that binds in a flipped orientation relative to normal E2 binding mode (113).”
BackgroundSelf-citationEstrogen receptor (ER)-β isoforms: A key to understanding ER-β signaling
Leung, Y.-K., Mak, P., Hassan, S., & Ho, S.-M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605676103 · Cited by 357
Shiau, A. K., Barstad, D., Radek, J. T., Meyers, M. J., Nettles, K. W., Katzenellenbogen, B. S., Katzenellenbogen, J. A., Agard, D. A., & Greene, G. L. (2002) · Nature Structural Biology · doi:10.1038/nsb787 · Cited by 356
Self-citationSoy Isoflavones—Benefits and Risks from Nature’s Selective Estrogen Receptor Modulators (SERMs)
Setchell, K. D. R. (2001) · Journal of the American College of Nutrition · doi:10.1080/07315724.2001.10719168 · Cited by 354
“The folding of helix-12 in particular governs the ability of the receptor complex to attract specific co-activator or co-repressor proteins [67,68] and this ultimately dictates the extent of agonist or antagonist actions [65].”
BackgroundPurine and Pyrimidine (P2) Receptors as Drug Targets
Jacobson, K. A., Jarvis, M. F., & Williams, M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020046y · Cited by 352
Structural Insights into the Mode of Action of a Pure Antiestrogen
Pike, A. C. W., Brzozowski, A. M., Walton, J., Hubbard, R. E., Thorsell, A.-G., Li, Y.-L., Gustafsson, J.-Å., & Carlquist, M. (2001) · Structure · doi:10.1016/s0969-2126(01)00568-8 · Cited by 347
Self-citationThe p KBHX Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists
Laurence, C., Brameld, K. A., Graton, J., Le Questel, J.-Y., & Renault, E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801331y · Cited by 346
Egea, P. F. (2000) · The EMBO Journal · doi:10.1093/emboj/19.11.2592 · Cited by 342
Kauppi, B., Jakob, C., Färnegårdh, M., Yang, J., Ahola, H., Alarcon, M., Calles, K., Engström, O., Harlan, J., Muchmore, S., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212711200 · Cited by 336
Self-citationReproductive Malformation of the Male Offspring Following Maternal Exposure to Estrogenic Chemicals
Gupta, C. (2000) · Proceedings of the Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.2000.22402.x · Cited by 334
Armstrong, A. F., & Valliant, J. F. (2007) · Dalton Transactions · doi:10.1039/b709843j · Cited by 333
Hlisníková, H., Petrovičová, I., Kolena, B., Šidlovská, M., & Sirotkin, A. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17186811 · Cited by 331
Input/output balance of estrogenic active compounds in a major municipal sewage plant in Germany
Körner, W., Bolz, U., Süßmuth, W., Hiller, G., Schuller, W., Hanf, V., & Hagenmaier, H. (2000) · Chemosphere · doi:10.1016/s0045-6535(99)00362-8 · Cited by 330
Estrogen Receptor Alpha in Human Breast Cancer: Occurrence and Significance
Ali, S., & Coombes, R. C. (2000) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1009594727358 · Cited by 329
“Ligand binding results in the realignment of helix 12, enabling co-regulators to associate (8,23).”
BackgroundAromatase inhibitors for breast cancer: lessons from the laboratory
Johnston, S. R. D., & Dowsett, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1211 · Cited by 326
“However, tamoxifen-bound ER still dimerizes and binds DNA, but the altered conformational shape of the SERM–ER complex compared with oestradiol leads to different downstream effect”
BackgroundSelective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer
Jordan, V. C., & O'Malley, B. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3886 · Cited by 324
The Role of Corepressors in Transcriptional Regulation by Nuclear Hormone Receptors
Privalsky, M. L. (2004) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.032802.155556 · Cited by 324
Mechanisms of gene regulation by vitamin D3 receptor: a network of coactivator interactions
Rachez, C., & Freedman, L. P. (2000) · Gene · doi:10.1016/s0378-1119(00)00052-4 · Cited by 323
An, J., Tzagarakis-Foster, C., Scharschmidt, T. C., Lomri, N., & Leitman, D. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100953200 · Cited by 323
Nuclear-Receptor Ligands and Ligand-Binding Domains
Weatherman, R. V., Fletterick, R. J., & Scanlan, T. S. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.559 · Cited by 322
2.1 Å Crystal Structure of Human PXR in Complex with the St. John's Wort Compound Hyperforin,
Watkins, R. E., Maglich, J. M., Moore, L. B., Wisely, G. B., Noble, S. M., Davis-Searles, P. R., Lambert, M. H., Kliewer, S. A., & Redinbo, M. R. (2003) · Biochemistry · doi:10.1021/bi0268753 · Cited by 319
A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation
Oberfield, J. L., Collins, J. L., Holmes, C. P., Goreham, D. M., Cooper, J. P., Cobb, J. E., Lenhard, J. M., Hull-Ryde, E. A., Mohr, C. P., Blanchard, S. G., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6102 · Cited by 316
Selective estrogen receptor modulation
Jordan, V. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00059-5 · Cited by 315
Sun, J., Meyers, M. J., Fink, B. E., Rajendran, R., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (1999) · Endocrinology · doi:10.1210/endo.140.2.6480 · Cited by 315
“antagonist activity of the bound ligand (20).”
Kalkhoven, E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.1.232 · Cited by 314
Isoflavones, lignans and stilbenes - origins, metabolism and potential importance to human health
Cassidy, A., Hanley, B., & Lamuela-Raventos, R. M. (2000) · Journal of the Science of Food and Agriculture · doi:10.1002/(sici)1097-0010(20000515)80:7<1044::aid-jsfa586>3.0.co;2-n · Cited by 313
Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids
Wisely, G. B., Miller, A. B., Davis, R. G., Thornquest, A. D., Johnson, R., Spitzer, T., Sefler, A., Shearer, B., Moore, J. T., Miller, A. B., et al. (2002) · Structure · doi:10.1016/s0969-2126(02)00829-8 · Cited by 311
Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity
Dennis, M. K., Field, A. S., Burai, R., Ramesh, C., Petrie, W. K., Bologa, C. G., Oprea, T. I., Yamaguchi, Y., Hayashi, S.-I., Sklar, L. A., et al. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.07.002 · Cited by 311
“In order to assess the structural basis of the observed low-affinity binding, we performed docking studies with the 3-dimensional X-ray crystal structure of the estrogenbound ligand binding domain of ERα (PDB ID 1ERE) [22].”
The biological role of estrogen receptors α and β in cancer
Pearce, S. T., & Jordan, V. C. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.003 · Cited by 311
“3A, green) is positioned over the ligand binding pocket in the ER −E2 complex[62,63], thereby generating a functional AF2 that is able to interact with coactivators.”
GPR30: A G protein-coupled receptor for estrogen
Prossnitz, E. R., Arterburn, J. B., & Sklar, L. A. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.12.010 · Cited by 310
“in 1986 (Greene et al., 1986) and the first crystal structure of an ER ligand-binding domain was described in 1997 ( Brzozowski et al., 1997 ).”
BackgroundEstrogen Receptor β: An Overview and Update
Zhao, C., Dahlman-Wright, K., & Gustafsson, J.-Å. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06003 · Cited by 309
“However, the amino acids lining the ligand-binding cavities of ERα and ERβ differ in two positions [Brzozowski et al., 1997; Pike et al., 1999].”
Self-citationSpengler, P., Körner, W., & Metzger, J. W. (2001) · Environmental Toxicology and Chemistry · doi:10.1002/etc.5620201001 · Cited by 308
Structural Basis for Bile Acid Binding and Activation of the Nuclear Receptor FXR
Mi, L.-Z., Devarakonda, S., Harp, J. M., Han, Q., Pellicciari, R., Willson, T. M., Khorasanizadeh, S., & Rastinejad, F. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00112-6 · Cited by 307
Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1
Zwijsen, R. M. L., Buckle, R. S., Hijmans, E. M., Loomans, C. J. M., & Bernards, R. (1998) · Genes & Development · doi:10.1101/gad.12.22.3488 · Cited by 305
Hong, H., Yang, L., & Stallcup, M. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22618 · Cited by 303
17β-Estradiol Degradation by TiO2 Photocatalysis as a Means of Reducing Estrogenic Activity
Ohko, Y., Iuchi, K.-I., Niwa, C., Tatsuma, T., Nakashima, T., Iguchi, T., Kubota, Y., & Fujishima, A. (2002) · Environmental Science & Technology · doi:10.1021/es011500a · Cited by 302
Differential estrogen receptor binding of estrogenic substances: a species comparison
Matthews, J., Celius, T., Halgren, R., & Zacharewski, T. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00126-6 · Cited by 302
“Despite the differences in sequence identity among species [14,17], ERs from all species harbor the same three equivalent amino acids to hERa (Glu353, Arg394 and His524) that participate in direct hydrogen bonds and stabilize E2 in the binding pocket [18,19].”
BackgroundMethodInfluentialEstrogen Receptors α and β Are Differentially Expressed in Developing Human Bone1
Bord, S., Horner, A., Beavan, S., & Compston, J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7513 · Cited by 300
“Once bound by estrogens, the ER undergoes a conformational change, allowing the receptor to interact with chromatin and to modulate the expression of target genes ( 4 ).”
BackgroundMolecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action
Dutertre, M., & Smith, C. L. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38923-2 · Cited by 299
“Various approaches, using either proteolytic peptide mapping, antibody epitope mapping, crystallography, or affinity selection of peptides, have shown that different ligands induce distinct receptor conformations in the LBD of both ERa and ERb, and that antiestrogens such as tamoxifen and raloxifene induce structures…”
The Molecular Pharmacology of SERMs
McDonnell, D. P. (1999) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(99)00177-0 · Cited by 299
Brown, N. M., & Setchell, K. D. R. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780282 · Cited by 297
“Isoflavones appear to be natural selective estrogen receptor modulators (SERMs) because of the manner in which they bind to estrogen receptors, particularly ERb (Brzozowski et al, 1997; Pike et al, 1999).”
Background
Metadata
- Authors
- Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M.
- Affiliations
- University of York (GB)
- Karo Pharma (Sweden) (SE)
- University of Chicago (US)
- Corresponding author
- Hubbard, Roderick E.
- ORCID
- Venue
- Nature
- Published
- 1997-10
- Volume
- 389
- Issue
- 6652
- Pages
- 753-758
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2101738855
- Cited by
- 3,355
- References
- 29
- Citations by year
- 2026: 49 · 2025: 55 · 2024: 55 · 2023: 61 · 2022: 62 · 2021: 91 · 2020: 55 · 2019: 75 · 2018: 73 · 2017: 65 · 2016: 72 · 2015: 74 · 2014: 94 · 2013: 105 · 2012: 104
- FWCI
- 94.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- oestrogen receptor, ligand-binding domain, estradiol, raloxifene, selective estrogen receptor modulators, crystal structure, transcriptional regulation
- MeSH terms
- Binding Sites, Estradiol, Estrogen Antagonists, Humans, Models, Molecular, Piperidines, Protein Conformation, Receptors, Estrogen, Crystallography, X-Ray, Raloxifene Hydrochloride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.